about
Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trialsRetrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae.Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.Protective effects of quercetin and hyperoside on renal fibrosis in rats with unilateral ureteral obstruction.Fibrinogen alpha chain precursor and apolipoprotein A-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics studyElevated levels of miR-155 in blood and urine from patients with nephrolithiasis.Metformin inhibits cell growth by upregulating microRNA-26a in renal cancer cells.Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model.Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1).Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer.Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9Nrdp1-mediated degradation of BRUCE decreases cell viability and induces apoptosis in human 786-O renal cell carcinoma cellsHigh expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder.Urinary angiotensinogen is elevated in patients with nephrolithiasis.Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21.Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels.Matrix metallopeptidase 2 (MMP2) mediates MHC class I polypeptide-related sequence A (MICA) shedding in renal cell carcinoma.VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α.Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a.Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.Urinary neutrophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis.Protective effects of SP600125 on renal ischemia-reperfusion injury in rats.Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats.Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling.GATA-3 is down-regulated in patients with clear cell renal carcinoma.Downregulation of pigment epithelium-derived factor is associated with increased epithelial-mesenchymal transition in bladder cancer.Epigallocatechin gallate attenuates interstitial cystitis in human bladder urothelium cells by modulating purinergic receptors.Protective effects of rosuvastatin in experimental renal failure rats via improved endothelial function.Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathyProtective effects of atorvastatin on chronic allograft nephropathy in ratsTherapeutic effect of Y-27632 on chronic allograft nephropathy in ratsCulture and Characterization of Circulating Endothelial Progenitor Cells in Patients with Renal Cell Carcinoma
P50
Q26864662-50ED07D7-B7AE-407E-B5EF-4774A37374ABQ33597689-19E00B98-E9FF-4A4B-9FAB-D2F382D2E276Q33629807-98913CBB-5E9F-45C2-A028-C6EF99F8427BQ33962196-7D1B494C-0213-4CE0-A52F-A616338E92A1Q34043307-6CDEBAC8-E1CE-45A1-BAAF-80107639A330Q34114226-4D0092A0-5561-46C0-94B2-D14F009A2066Q34547703-9B4B3382-DA7B-4B54-96D8-D5234D0E53AFQ35217548-8E587663-4AA6-4010-9268-740127A769C8Q35678368-852E83FC-2CCE-4B6D-969C-7E4FDA675C04Q36430654-08ABB0A0-761F-4E0C-A869-FE6133137B92Q36741062-FE302BC3-F374-4FC7-8870-7F3CBC8E46BEQ37108323-E7D47F28-79DE-4ACE-A23E-C8892BDE5759Q37277780-186AAB39-93AC-4718-B0F1-063B2DC76785Q37452303-907ADF8E-1B86-4118-9429-69EB25C079DBQ37725522-FA8B0705-CF71-429B-A1A4-7B880571F035Q38303300-1509A283-95B2-417F-8108-467E177A5393Q38904830-20BC58A8-85F8-448A-8D75-393AB3384964Q39030939-2F6B9437-C363-4B43-92EC-3553A15DBE57Q39037363-B58BE315-6073-4180-8C4C-55A51739050BQ39068673-7672346F-63F6-45D6-B6F0-8185CA34C391Q39918008-9FD073E4-5116-4797-A9B4-F06B3004E564Q43825655-66FEB96B-E0BB-48D5-B395-8A26A91B27A1Q44328448-379F6166-62AA-4FDC-BF00-2579FD1B301DQ46511489-092DF164-C5E4-4716-A396-FD554270446BQ47151111-75BEA025-12ED-4387-B390-DEA4A7AD4063Q47882179-25B54365-4FE8-4DCC-9FF2-C7063EB6A2A8Q51490159-D0B08C85-64D1-4B35-8888-ECD314B69128Q54278658-53C4D10E-87F9-466E-A1FD-50017474360EQ54312332-476BB1C4-D6A2-4575-88C4-1A6DCB96175BQ80502276-8B6981D2-C6FD-4210-A766-69D3E619F136Q80605792-9F452BA6-E306-4F55-9AE2-70479ACB2166Q84201879-5A11277A-1A9F-46A8-90C2-FF4AD7507480Q86687922-C474ACCC-4F86-4E72-B7D4-B96EEB3E2F4B
P50
description
researcher
@en
հետազոտող
@hy
name
Min Liu
@ast
Min Liu
@en
Min Liu
@es
Min Liu
@nl
Min Liu
@sl
type
label
Min Liu
@ast
Min Liu
@en
Min Liu
@es
Min Liu
@nl
Min Liu
@sl
prefLabel
Min Liu
@ast
Min Liu
@en
Min Liu
@es
Min Liu
@nl
Min Liu
@sl
P214
P106
P214
P31
P496
0000-0002-8117-4808
P7859
viaf-316019458